Intravitreal injection with anti-vascular endothelial growth factor (anti-VEGF) has revolutionized the treatment of wet age-related macular degeneration, as well as diabetic maculopathy and retinal vein occlusions during the last decade. This evidence concerns the gene VEGFA and diabetic maculopathy.